News

Appoints oncologist Prof. Sarah Blagden to its Scientific Advisory Board. Oxford Drug Design, the Oxford-based AI drug discovery company applying its pioneering […]

Targeted protein degradation discovery programme to harness artificial intelligence to identify new E3 Ligase-based therapeutic strategies. Oxford Drug Design, a biotechnology company […]

Oxford Drug Design, the Oxford-based AI drug discovery company applying its pioneering AI platform to develop novel molecules for use in cancer […]

Dr Aras Asaad presented his work in exploiting existing 2D image-based deep learning architectures to capture 3D molecular information at this year’s […]

Oxford Drug Design’s Founder and current Chairman, Prof. W. Graham Richards CBE FRS has recently written an account of the origins of […]

Paul Finn, CSO, will be attending the 28th tRNA Conference, 12-16 June 2022 in Columbus, Ohio, USA.  On 13 June at 4:45pm […]

Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised $2.7M (£2.2M) in funding […]

Paul Finn, CSO, will be attending ASM Microbe 2022, 9-13 June in Washington D.C. USA and making an Oral Presentation on Saturday […]

Dr. Grace Edmund was selected to attend the Interdisciplinary Course on Antibiotics and Resistance (ICARe) hosted by Les Pensières Center for Global […]

Marco Albanese recently presented his work in designing novel histidine kinases inhibitors at the CARTNET Symposium in Valencia. He described using Oxford […]

Oxford Drug Design Board of Directors announces the appointment of Dr. Alan D. Roth Chief Executive Officer, effective immediately. Alan takes over […]

Oxford Drug Design recently attended both the virtual 3rd RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry and UK-QSAR Autumn 2020 meetings. Dr […]

Prof. Graham Richards recently spoke to Dr. Michelle Dipp, Co-Founder and Managing Partner of Biospring, on the topic of computer-aided molecular design.

Oxford Drug Design is proud to have been shortlisted for this year’s CogX award for ‘Best AI product in health’. CogX is […]

Unfortunately due to COVID-19 the events listed have been cancelled. We look forward to meeting you at future events. Oxford Drug Design […]

Oxford University biotech spin-out receives over £2 million to take its drug discovery programme to the next level. Oxford Drug Design Limited […]

Oxford Drug Design recently attended an event at the Said Buisness School, in Oxford showcasing the latest developments of Collaborative Drug Discovery’s […]

Oxford Drug Design announced today success in securing funds, totalling over £8m, from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the UK […]

Dr Michael Charlton recently presented our work in designing novel aminoacyl tRNA synthetase inhibitors at the Chemical Computing Group’s European User Group […]

Marco Albanese recently presented a poster on using fragment-based approaches to discover compounds targeting the ATP-binding domain of bacterial histidine kinases at […]

Prof. Paul Finn presented on a major cause of failure of antibacterial drug discovery projects, failure to accumulate sufficiently at the site […]

Dr Paul Finn attended the theory and modelling chemical sciences annual symposium in Bristol. The theory and modelling in chemical sciences centre for doctoral […]

Oxford Drug Design attended the JPI-AMR workshop on “Getting small drug-like molecules into Gram-negative bacteria”. This workshop provided an excellent opportunity to […]

Dr. Jerome Wicker recently presented our latest work on the effect of charge and conformation on enrichment of DUD-E targets. Using both […]

Oxford Drug Design is pleased to announce the appointment of Dr. Pamela Brown FRSC to the company’s Scientific Advisory Board. Dr. Brown […]

Oxford Drug Design Chairman and Co-founder Prof. W. Graham Richards has been elected a Fellow of the Royal Society. Fellowship is awarded […]

Oxford Drug Design Chairman and Co-founder Prof. W. Graham Richards has been awarded the Richard J. Bolte Sr. Award for Supporting Industries. […]

Oxford Drug Design attended the joint UK-QSAR/Molecular Graphics and Modelling Society (MGMS) conference on the theme of “Structure Activity Relationships”. Dr Grace […]

Oxford Drug Design has contributed to an article in the March edition of Chemistry World. The article, entitled “Countdown to the last […]

ODD scientists and collaborators have published a research paper describing the discovery of a new class of aminoacyl-tRNA synthetase inhibitors, N-Leucinyl benzenesulfonamides. […]

Dr. Michael Charlton presented a review of literature analyses of the physical properties of antibacterial compounds. This included an emphasis on our […]

Oxford Drug Design has started work on a new €3.4 Million Horizon 2020 Marie Curie European Training Network – CARTNET, “Combating Antimicrobial Resistance […]

Dr. Michael Charlton and Dr. Grace Edmund recently reported our work in the design of novel compounds to target the synthetic active […]

The European Commission has awarded 3.4 Million Euro under the Horizon 2020 programme to a new Marie Curie European Training Network – CARTNET, […]

Oxford Drug Design is pleased to announce the addition of Prof. David Livermore to our Scientific Advisory Board. David Livermore gained his […]

Oxford Drug Design is pleased to announce the appointment of James B. Kahn, M.D. FIDSA, to the company’s Scientific Advisory Board. Dr. […]

InhibOx has relaunched as Oxford Drug Design to reflect its transition to a biotechnology company focused on internal drug discovery. Our lead […]

Oxford Drug Design has raised nearly $2m (£1.5m) of private investment to enable it to progress a novel antibacterial programme and continue […]

Oxford Drug Design (formerly InhibOx) has started work on a $1.1m (£900k) grant funded project to develop novel antibiotics. The project started […]